<DOC>
	<DOCNO>NCT02171325</DOCNO>
	<brief_summary>The purpose study identify appropriate dose irinotecan dose escalation ( dose climb ) test . The study would provide rationale regimen decision future phase III clinical trial , irinotecan combine cisplatin ( IP ) select therapeutic drug .</brief_summary>
	<brief_title>Study Different Doses Irinotecan Cisplatin First-line Extensive-stage Small-cell Lung Cancer Treatment</brief_title>
	<detailed_description>To determine Maximum Tolerated Dose ( MTD ) Limiting Toxicity ( DLTs ) irinotecan patient extensive stage small cell lung cancer treat irinotecan plus cisplatin</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Age 18 65 year , male female 2 . Histologically cytologically confirm extensive stage .small cell lung cancer ( SCLC ) （except metastases pleural effusion） 3 . No prior chemotherapy 4 . Metastatic lesion treat 14 day palliative radiation therapy surgery 5 . With measurable tumor lesion ( Nonirradiated part ) , ( RECIST 1.1 : Without radiotherapy , long diameter 10mm CT MRI , except lymph node need short diameter need 15mm , lesion accurately evaluate repeatedly measurable ) 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 7 . Expected survival ≥ 3months 8 . Marrow , kidney , liver , heart lung well function , absolute count absolute neutrophil coun ( ANC ) ≥ 2.0 × 109 / L blood platelet ( PLT ) ≥ 100 × 109 / L Hb≥ 90g / L conjugative bilirubin ( CB ) ≤ upper limit normal ( ULN ) × 1.5 Aspartate transaminase ( AST ) ( glutamic oxalacetic transaminase , GOT ) : ≤ upper limit normal ( ULN ) × 2.5 Alanine aminotransferase ( ALT ) ( Glutamate Pyruvate Transaminase , GPT ) : ≤ ULN × 2.5 Serum creatinine : ≤ ULN calculate creatinine clearance≥ 60 ml / min ( PT INR ) ≤ ULN × 1.5 ECG : abnormality need treatment 9 . No pregnancy pregnancy demand end study within six month 10 . Must provide write informed consent . 1 . Patient platinum compound allergy history 2 . Patient active ulcer disease chronic enteritis patient 3 . Primary lesion ( ) ( ) treat Surgery radiation 4 . Patient receive Immune drug treatment antilung cancer indication anticancer Chinese traditional medicine treatment within two week 5 . Patients interstitial pneumonia pulmonary fibrosis 6 . Brain metastasis require treatment 7 . Patient bronchus bronchial stenosis blockage superior vena cava syndrome cause serious invasion 8 . Patients severe infection , severe abnormal secretion ( Anti Diuretic Hormone , ADH ) syndrome , poorly control diabetes , severe complication require treatment vena cava syndrome 9 . Severe cardiovascular disease : hypertension medical treatment control , unstable angina , myocardial infarction within last June history congestive heart failure &gt; 3 ( NYHA ) severe arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>irinotecan</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
</DOC>